About CLINUVEL

Contact

Head Office

CLINUVEL PHARMACEUTICALS LIMITED,
Level 6,
15 Queen Street,
Melbourne
Victoria 3000
Australia

Tel: +61 3 9660 4900
Fax: +61 3 9660 4909
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

UK office

Wesley House,
Bull Hill
Leatherhead, KT22 7AH
United Kingdom

Tel: +44 1372 860 765

Singapore office

9 Temasek Blvd #29-01
Singapore 038989

US Office

PO BOX 7388,
Menlo Park, CA 94026

Swiss Office

Zugerstrasse 76a,
6340 Baar,
Switzerland

Tel: +41 41 763 1782
Fax: +41 41 763 1784
 

 

 

CLINUVEL receives a large number of inquiries every day. For a list of frequently asked questions, please click here.

For more information on CLINUVEL’s program for SCENESSE® in EPP, please go to the following page.

For more information on CLINUVEL’s program for SCENESSE® in Vitiligo, please go to the following page.

If you have any additional questions, you can send us a message by filling out this online form.
If you have any investor related questions, you can send us a message by filling out this online form.
If you experience any side effects while using a CLINUVEL product, please feel free to contact us at This email address is being protected from spambots. You need JavaScript enabled to view it.

Latest Company Announcements

10 January 2018

Chair Letter to Shareholders

Whilst the Board of CLINUVEL looks back on a very successful 2017 it must now look forward to exciting times ahead.

Read More
21 December 2017

CLINUVEL Newsletter - December 2017

In the last communiqué of the calendar year, we take a breath and contemplate CLINUVEL’s status, a holding position for our teams over Christmas in the run up to a full 2018.

Read More
20 December 2017

Preliminary recommendation by NICE not to include SCENESSE® for reimbursement by NHS England

CLINUVEL PHARMACEUTICALS LTD today announced that the first draft assessment from England’s National Institute for Health and Care Excellence (NICE) has been published,

Read More
07 December 2017

CLINUVEL Newsletter - December 2017

The CLINUVEL team is looking with much optimism and energy to the start of 2018.

Read More
05 December 2017

Lapse and Forfeit of Unlisted Conditional Performance Rights

Lapse and Forfeit of Unlisted Conditional Performance Rights

Read More
05 December 2017

Appendix 3Z - Final Director’s Interest Notice

Final Director’s Interest Notice

Read More

Quick Links